ArticleJournal of the International AIDS Society2026
Optimizing HIV Spending Among Key Populations in Five Latin American and Caribbean Countries: A Mathematical Modelling Study.
Article in Journal of the International AIDS Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Latin America and the Caribbean: Socioeconomic Realities and Implications for Health and HIV Responses.Journal of the International AIDS Society · 2026Article
- Optimizing HIV Spending Among Key Populations in Five Latin American and Caribbean Countries: A Mathematical Modelling Study.Journal of the International AIDS Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
introductionFrom 2010 to 2024, the Latin America region experienced a 13% increase in new HIV acquisitions, while progress in reducing HIV acquisitions has slowed in the Caribbean. We conducted allocative efficiency studies for five countries in the Latin America and Caribbean region, aiming to estimate how HIV spending could be optimally allocated for maximal impact.
methodsBetween 2021 and 2025, we collaborated with national partners in Colombia, Costa Rica, Dominican Republic, El Salvador and Honduras to develop national Optima HIV models incorporating country-specific key populations. Prevention, testing and antiretroviral therapy (ART) interventions were parameterized using country-specific unit costs, coverage estimates and effectiveness values. For each country, we projected HIV incidence, mortality and treatment resource needs from 2025 to 2030 for multiple scenarios: fixed intervention coverage (status quo), fixed spending allocations (counterfactual), and most recent spending optimized across interventions to minimize cumulative HIV acquisitions and HIV-related deaths.
resultsWith the status quo continued, HIV incidence was projected to decline by 2030 in two countries, stabilize in two and increase in one country. Transgender women and men who have sex with men have the highest incidence rate. Due to ongoing increases in the number of diagnosed people living with HIV, by 2030, annual ART resources will need to increase by 1%-15% to maintain the existing treatment coverage. Compared with the counterfactual (fixed spending) scenario, optimization of existing resources could avert 18%-33% of new HIV acquisitions and 5%-31% of HIV-related deaths over 2025-2030 by prioritizing primarily ART. If modelled ART unit costs reduce by 25%, then 23%-69% of projected HIV acquisitions and 8%-61% of HIV-related deaths could be averted by reinvesting savings to scale-up interventions for country-specific key populations instead of lower-yield interventions such as untargeted HIV testing.
conclusionsThis multi-country modelling study demonstrates the potential to reduce new HIV acquisitions and HIV-related deaths across Latin America and the Caribbean without increasing total spending. Recent reductions in treatment costs provide greater flexibility to invest in key population-focused services which could amplify epidemic impact. The findings underscore the importance of aligning HIV resources with epidemic drivers and expanding targeted prevention for key populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.